JP2017536085A5 - - Google Patents

Download PDF

Info

Publication number
JP2017536085A5
JP2017536085A5 JP2017515243A JP2017515243A JP2017536085A5 JP 2017536085 A5 JP2017536085 A5 JP 2017536085A5 JP 2017515243 A JP2017515243 A JP 2017515243A JP 2017515243 A JP2017515243 A JP 2017515243A JP 2017536085 A5 JP2017536085 A5 JP 2017536085A5
Authority
JP
Japan
Prior art keywords
cancer
genes
gene
expression
protein encoded
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017515243A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017536085A (ja
JP6730983B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/071524 external-priority patent/WO2016042164A1/en
Publication of JP2017536085A publication Critical patent/JP2017536085A/ja
Publication of JP2017536085A5 publication Critical patent/JP2017536085A5/ja
Application granted granted Critical
Publication of JP6730983B2 publication Critical patent/JP6730983B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017515243A 2014-09-19 2015-09-18 癌の再発リスクを予測する方法 Active JP6730983B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14185673 2014-09-19
EP14185673.2 2014-09-19
PCT/EP2015/071524 WO2016042164A1 (en) 2014-09-19 2015-09-18 A method of predicting risk of recurrence of cancer

Publications (3)

Publication Number Publication Date
JP2017536085A JP2017536085A (ja) 2017-12-07
JP2017536085A5 true JP2017536085A5 (cg-RX-API-DMAC7.html) 2018-11-08
JP6730983B2 JP6730983B2 (ja) 2020-07-29

Family

ID=51589137

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017515243A Active JP6730983B2 (ja) 2014-09-19 2015-09-18 癌の再発リスクを予測する方法

Country Status (9)

Country Link
US (4) US10557175B2 (cg-RX-API-DMAC7.html)
EP (1) EP3194621B1 (cg-RX-API-DMAC7.html)
JP (1) JP6730983B2 (cg-RX-API-DMAC7.html)
AU (1) AU2015316711B2 (cg-RX-API-DMAC7.html)
CA (1) CA2961725C (cg-RX-API-DMAC7.html)
ES (1) ES2753625T3 (cg-RX-API-DMAC7.html)
IL (1) IL251141B (cg-RX-API-DMAC7.html)
NZ (1) NZ730124A (cg-RX-API-DMAC7.html)
WO (1) WO2016042164A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2753625T3 (es) * 2014-09-19 2020-04-13 The Provost Fellows Found Scholars & The Other Members Of Board Of The College Of The Holy & Undiv T Un método para predecir el riesgo de recaída del cáncer
WO2017189976A1 (en) * 2016-04-29 2017-11-02 Board Of Regents, The University Of Texas System Targeted measure of transcriptional activity related to hormone receptors
CN106039312B (zh) * 2016-05-25 2019-07-23 中山大学肿瘤防治中心 Znf367基因在制备治疗乳腺癌药物、诊断及预后评估试剂中的应用
GB201709417D0 (en) * 2017-06-14 2017-07-26 Inst Of Cancer Research: Royal Cancer Hospital Cyclin dependent kinase 4/6 inhibitors for use in methods of treating cancer
USD875753S1 (en) * 2018-03-06 2020-02-18 Ventana Medical Systems, Inc. Display screen or portion thereof with graphical user interface for biological slide scanning
US20240018597A1 (en) * 2019-10-09 2024-01-18 The University Of North Carolina At Chapel Hill DNA Copy Number Alterations (CNAs) to Determine Cancer Phenotypes
EP4253567A1 (en) 2022-03-31 2023-10-04 OncoAssure Limited A method of predicting risk of an aggressive or recurrent cancer
WO2025239278A1 (ja) * 2024-05-16 2025-11-20 公益財団法人がん研究会 リンパ管侵襲またはリンパ節転移の可能性を判定するための検査方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3470535T3 (pl) * 2003-06-24 2020-08-24 Genomic Health, Inc. Prognozowanie prawdopodobieństwa ponownego wystąpienia raka
US20080275652A1 (en) * 2005-05-13 2008-11-06 Universite Libre De Bruxelles Gene-based algorithmic cancer prognosis
US7914988B1 (en) 2006-03-31 2011-03-29 Illumina, Inc. Gene expression profiles to predict relapse of prostate cancer
US9605319B2 (en) 2010-08-30 2017-03-28 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
EP2549399A1 (en) * 2011-07-19 2013-01-23 Koninklijke Philips Electronics N.V. Assessment of Wnt pathway activity using probabilistic modeling of target gene expression
WO2014066796A2 (en) * 2012-10-25 2014-05-01 Myriad Genetics, Inc. Breast cancer prognosis signatures
WO2014130825A1 (en) 2013-02-21 2014-08-28 Myriad Genetics, Inc. Gene signatures for lung cancer prognosis and therapy selection
ES2753625T3 (es) * 2014-09-19 2020-04-13 The Provost Fellows Found Scholars & The Other Members Of Board Of The College Of The Holy & Undiv T Un método para predecir el riesgo de recaída del cáncer

Similar Documents

Publication Publication Date Title
JP2017536085A5 (cg-RX-API-DMAC7.html)
Lv et al. miRNA expression patterns in chemoresistant breast cancer tissues
Mao et al. A 15-long non-coding RNA signature to improve prognosis prediction of cervical squamous cell carcinoma
Ko et al. MicroRNA expression profiling of esophageal cancer before and after induction chemoradiotherapy
Chan et al. MiR-378 as a biomarker for response to anti-angiogenic treatment in ovarian cancer
Wang et al. High expression of miR-532-5p, a tumor suppressor, leads to better prognosis in ovarian cancer both in vivo and in vitro
Kim et al. Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing
WO2019075251A3 (en) Cancer score for assessment and response prediction from biological fluids
Li et al. Circulating microRNA-137 is a potential biomarker for human glioblastoma.
WO2013098797A3 (en) Diagnostic tests for predicting prognosis, recurrence, resistance or sensitivity to therapy and metastatic status in cancer
Xu et al. hsa-miR-135a-1 inhibits prostate cancer cell growth and migration by targeting EGFR
Jung et al. EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI
Wang et al. MiR-9-5p suppresses cell metastasis and epithelial-mesenchymal transition through targeting FOXP2 and predicts prognosis of colorectal carcinoma.
Ahmad et al. HDAC-4 regulates claudin-2 expression in EGFR-ERK1/2 dependent manner to regulate colonic epithelial cell differentiation
Liu et al. Knockdown of thrombospondin 2 inhibits metastasis through modulation of PI3K signaling pathway in uveal melanoma cell line M23.
Brkic et al. An analysis of distant metastasis cases from HPV-associated oropharyngeal squamous cell carcinoma
Baker et al. Lower preoperative quality of life increases postoperative risk of adverse events in women with endometrial cancer: results from the LACE trial
Kravets et al. The study of prognostic value of microRNAs (miR-10b and-155) and CDKN2A/P16INK4A in oral squamous cell carcinoma
TWI671653B (zh) 三陰性乳癌的次分類及方法
Mendes et al. Could be FOXO3a, miR-96-5p and miR-182-5p useful for Brazilian women with luminal A and triple negative breast cancers prognosis and target therapy?
WO2022094197A1 (en) Synthetic lethality-mediated precision oncology via tumor transcriptome
Penrod et al. Predicting targeted drug combinations based on Pareto optimal patterns of coexpression network connectivity
Severson et al. Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patients
Samlowski et al. 220 Real-world outcomes of patients with resected stage IIIA melanoma treated with adjuvant nivolumab
Kano et al. 532eP Salvage androgen-deprivation therapy as potential treatment for recurrence after robot-assisted radical prostatectomy